McGill University Health Centre in Montreal is one of the leading academic health centres in the world. They will be participating in…
Patient five has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540…
Research Ethics Board approval has been obtained to move TLD-1433 to a Phase II trial for non-muscle invasive bladder cancer, using the…
Three patients (patients four, five and six) were enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with patient 4 successfully achieving…
Patients five and six remain cancer-free after one year and nine months, respectively, of their single treatment with TLD-1433! In other news,…
Following the success of Patient 5, Patient 6 has now also demonstrated no recurrence of bladder cancer at the 180 day clinical…
Patient 5 tolerated the single-dose treatment well, and has demonstrated no tumor recurrence or presence of disease at the 180 day clinical…
Based on the encouraging results of the first patients in the trial, the Medical and Scientific Advisory Board (“MSAB”) unanimously recommended the…
Theralase has released three videos that were presented at its annual meeting. They cover the successful completion of the Phase Ib trial,…
Very encouraging news from the clinic! Patient Five shows no clinical evidence or presence of NMIBC (non muscle invasive bladder cancer) at…